NAD+: The Research Behind the Molecule
For laboratory and research use only. This article summarises published scientific research on NAD+ and related compounds. Neurovia’s NAD+ products are not intended for human consumption. See our disclaimer.
NAD+: The Research Behind the Molecule
NAD+ (Nicotinamide Adenine Dinucleotide) is one of the most fundamentally important molecules in cellular biology. Present in every living cell, it functions as an essential coenzyme in hundreds of metabolic reactions — and has become one of the most researched molecules in the field of ageing biology over the past two decades.
This article provides an evidence-based overview of NAD+: its biological role, the published research landscape in ageing and metabolism, the relationship between NAD+ and its precursor NMN, delivery format research, and supply options for laboratory use.
What Is NAD+?
NAD+ (Nicotinamide Adenine Dinucleotide, oxidised form) is a dinucleotide coenzyme found in all living cells. It exists in two interconvertible forms:
- NAD+ — the oxidised form, which accepts electrons in metabolic reactions
- NADH — the reduced form, which donates electrons
Molecular profile:
- Molecular weight: ~663 Da (NAD+)
- Components: Nicotinamide (a form of vitamin B3) + adenosine + two phosphate groups
- Function: Electron carrier in redox reactions; substrate for NAD+-consuming enzymes
NAD+ is not a peptide in the strict biochemical sense — it is a dinucleotide coenzyme. However, it is commonly categorised alongside research peptides by suppliers due to its research context, administration format, and the research communities that study it.
NAD+ in Cellular Metabolism
The primary biological role of NAD+ is as an electron carrier in cellular energy metabolism. In glycolysis and the citric acid cycle, NAD+ accepts electrons (becoming NADH), which are then used in the electron transport chain to generate ATP — the cell’s primary energy currency.
Beyond energy metabolism, NAD+ serves as a substrate for several important enzyme classes:
Sirtuins (SIRTs 1–7) — A family of NAD+-dependent deacetylases that regulate gene expression, DNA repair, metabolic regulation, and stress responses. Sirtuin activity is directly dependent on NAD+ availability, which has made the NAD+/sirtuin axis a central focus of ageing biology research.
PARPs (Poly-ADP ribose polymerases) — NAD+-consuming enzymes involved in DNA damage repair. PARP activation in response to DNA damage consumes NAD+, and excessive PARP activity has been studied as a contributor to NAD+ depletion in ageing cells.
CD38 — An NAD+-consuming enzyme involved in calcium signalling, immune function, and inflammation. Research has identified CD38 as a significant contributor to age-related NAD+ decline.
The NAD+ Decline and Ageing Research
One of the most significant findings in NAD+ biology is the consistent observation, across multiple published studies and species, that cellular NAD+ levels decline with age.
Published research in rodent models by David Sinclair’s group at Harvard, Shin-ichiro Imai’s group at Washington University, and Johan Auwerx’s group at EPFL, among others, has examined this NAD+ decline and its consequences in animal models:
- Reduced sirtuin activity in aged tissues (due to lower NAD+ substrate availability)
- Impaired mitochondrial function
- Reduced DNA repair efficiency
- Metabolic dysfunction in muscle, liver, and other tissues
These findings, published in journals including Cell, Cell Metabolism, Nature Medicine, and Science, have made NAD one of the most actively researched molecules in the longevity biology field.
NAD+ and NMN: The Precursor Research
NMN (Nicotinamide Mononucleotide) is a direct precursor to the molecule in one of the major this compound biosynthesis pathways (the salvage pathway). NMN is converted to it by the enzyme NMNAT (NMN adenylyltransferase).
The rationale for studying NMN as a research intervention is that direct NAD administration faces bioavailability challenges — the molecule does not easily cross cell membranes — whereas precursor molecules may be more readily taken up by cells and converted intracellularly to this compound.
Published NMN research includes:
- Imai et al. (Cell Metabolism, 2013, 2016) — preclinical studies demonstrating that NMN supplementation in aged mice restored it levels in tissues and improved markers of metabolic function
- Multiple subsequent animal studies from independent groups examining NMN’s effects on specific tissues including muscle, liver, brain, and vasculature in rodent models
- Clinical research — a growing number of human clinical trials examining NMN administration and its effects on NAD levels and metabolic markers, with several published in peer-reviewed journals
What Is the Difference Between NAD+ and NMN?
the molecule is the active coenzyme. NMN is a direct precursor that the body converts to this compound. Research has investigated both:
- Direct it administration — including intravenous formats studied in clinical and preclinical contexts
- NMN administration — studied as an oral and other-format precursor approach to raising cellular NAD
Published research has examined the relative bioavailability and tissue uptake of different the molecule precursors, including NMN and NR (Nicotinamide Riboside), with different findings across tissues and species.
NAD+ Delivery Format Research
An active area of published research concerns how this compound and its precursors are best delivered for research and clinical purposes. Several formats have been studied:
Intravenous (IV) it — Published research and clinical case series have examined IV NAD administration, noting that IV delivery bypasses the bioavailability challenges associated with oral administration. Research has examined the molecule pharmacokinetics following IV administration in human subjects.
Nasal spray this compound — Emerging research interest in nasal delivery of it relates to the potential for direct CNS delivery via the olfactory route, bypassing the blood-brain barrier. Published preclinical research on intranasal peptide and small molecule delivery informs this area, though specific published data on nasal NAD delivery remains limited compared to IV formats.
Oral NMN/NR — The most extensively published non-IV format, with multiple clinical trials examining oral NMN and NR and their effects on blood and tissue the molecule levels.
Supply Format for Research
Neurovia supplies the following this compound-related research formats:
- it 1000mg — lyophilised vial for laboratory research
- NAD Nasal Spray — intranasal research delivery format
- NMN Capsules 500mg — oral precursor format for research
All supplied at 99% purity, third-party tested, with Certificate of Analysis available.
Further reading: peer-reviewed research on the molecule (PubMed).
Frequently Asked Questions
What is this compound and why is it researched?
it (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, essential for energy metabolism and as a substrate for sirtuin, PARP, and CD38 enzymes. It is researched extensively in ageing biology because cellular NAD levels decline with age across multiple species, and published research in animal models has examined the consequences of this decline and the effects of restoring the molecule levels.
What does this compound research show?
Published research — primarily in animal models — has associated it decline with age-related impairments in mitochondrial function, sirtuin activity, DNA repair, and metabolic health. Studies from groups at Harvard, Washington University, and EPFL have published preclinical findings on NAD restoration in aged animals, with a growing clinical research literature in humans.
What is the difference between the molecule and NMN?
this compound is the active coenzyme. NMN (Nicotinamide Mononucleotide) is a direct precursor to it in the salvage biosynthesis pathway. Research has examined NMN as an approach to raising cellular NAD levels, given that direct the molecule supplementation faces bioavailability challenges at the cellular level.
What is NAD nasal spray research?
Nasal spray delivery of this compound is studied in the context of potential direct CNS delivery via the olfactory route. Published preclinical research on intranasal delivery of bioactive compounds informs this area. It represents an emerging research format with more limited specific published data compared to IV and oral it precursor research.
What is NAD IV research?
NAD intravenous administration has been studied in clinical and preclinical contexts, primarily as a way to circumvent the bioavailability limitations of oral delivery. Published pharmacokinetic studies have examined blood the molecule levels following IV administration in human subjects.
What is this compound ageing research?
it ageing research concerns the consistent finding that cellular NAD levels decline with age across multiple species, and the examination of whether restoring the molecule levels can reverse or slow age-associated cellular dysfunction. Key research groups include those of David Sinclair (Harvard), Shin-ichiro Imai (Washington University), and Johan Auwerx (EPFL), with findings published in top-tier journals.
Is NMN better than this compound for research?
This depends on the research question. Published research suggests NMN is more readily taken up by some cell types than it directly. However, pharmacokinetics vary by tissue and delivery route. Both formats have distinct published research literatures, and the choice for any specific research application depends on the experimental design and tissue system under study.
This article summarises published peer-reviewed research on NAD and related compounds and is provided for informational purposes only. Neurovia’s the molecule products are supplied for laboratory research use only and are not intended for human consumption. Full disclaimer →